Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS
(2007) In Neurourology and Urodynamics 26(6). p.928-933- Abstract
- Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT... (More)
- Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT symptoms (LUTS), have yielded favorable results. Thus, positive effects of the PDE 5 inhibitors sildenafil and tadalafil on symptoms and quality of life in men with LUTS, erectile dysfunction, and BPH have also been demonstrated. These effects may be due to effects on cGMP signaling and/or modification of afferent input from bladder, urethral, and prostate tissue. This review gives an update on the distribution of PDEs in structures relevant for LUT function, and discusses how inhibition of these enzymes can contribute to beneficial effects on LUTS. Information for the review was obtained from searches of the PubMed database, and from the authors' files. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/655117
- author
- Andersson, Karl-Erik LU ; Uckert, Stefan ; Stief, Christian and Hedlund, Petter LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- prostatic hypertrophy(BPH), (cGMP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate, sildenafil, tadalafil, vinpocetine
- in
- Neurourology and Urodynamics
- volume
- 26
- issue
- 6
- pages
- 928 - 933
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000250196200008
- scopus:35148853274
- ISSN
- 0733-2467
- DOI
- 10.1002/nau.20485
- language
- English
- LU publication?
- yes
- id
- 45edb0d2-7968-49ab-9a28-600cc0a5d47f (old id 655117)
- date added to LUP
- 2016-04-01 11:41:38
- date last changed
- 2022-04-05 03:30:19
@article{45edb0d2-7968-49ab-9a28-600cc0a5d47f, abstract = {{Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT symptoms (LUTS), have yielded favorable results. Thus, positive effects of the PDE 5 inhibitors sildenafil and tadalafil on symptoms and quality of life in men with LUTS, erectile dysfunction, and BPH have also been demonstrated. These effects may be due to effects on cGMP signaling and/or modification of afferent input from bladder, urethral, and prostate tissue. This review gives an update on the distribution of PDEs in structures relevant for LUT function, and discusses how inhibition of these enzymes can contribute to beneficial effects on LUTS. Information for the review was obtained from searches of the PubMed database, and from the authors' files.}}, author = {{Andersson, Karl-Erik and Uckert, Stefan and Stief, Christian and Hedlund, Petter}}, issn = {{0733-2467}}, keywords = {{prostatic hypertrophy(BPH); (cGMP); cyclic adenosine monophosphate (cAMP); cyclic guanosine monophosphate; sildenafil; tadalafil; vinpocetine}}, language = {{eng}}, number = {{6}}, pages = {{928--933}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Neurourology and Urodynamics}}, title = {{Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS}}, url = {{http://dx.doi.org/10.1002/nau.20485}}, doi = {{10.1002/nau.20485}}, volume = {{26}}, year = {{2007}}, }